HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum

Synapse

Volumn 66, Issue 8, 2012, Pages 755-757

  Theodore, Shaji ^a   Cass, Wayne A ^b   Dwoskin, Linda P ^c   Maragos, William F ^a,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Neurology Service   (United States)

Author keywords

Basal ganglia; Dopamine; Neurodegeneration; Striatum

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; RECOMBINANT PROTEIN; RECOMBINANT TAT[1-72] PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIV-1; MALE; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC VESICLES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84861670068     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21564     Document Type: Article

References (10)

1. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC. 1998. Variable progression of HIV-associated dementia. Neurology 50: 1814-1820.
2. Brown JM, Hanson GR, Fleckenstein AE. 2000. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74: 2221-2223.
3. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF. 2003. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984: 133-142.
4. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M. 2000. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14: 222-227.
5. Navia BA, Jordan BD, Price RW. 1986. The AIDS dementia complex. I. Clinical features. Ann Neurol 19: 517-524.
6. Teng L, Crooks PA, Sonsalla PK, Dwoskin LP. 1997. Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: Differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J Pharmacol Exp Ther 280: 1432-1444.
7. Theodore S, Cass WA, Maragos WF. 2006a. Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Exp Neurol 199: 490-498.
8. Theodore S, Cass WA, Maragos WF. 2006b. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137: 925-935.
9. Theodore S, Cass WA, Nath A, Maragos WF. 2007. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr HIV Res 5: 301-313.
10. Zhu J, Mactutus CF, Wallace DR, Booze RM. 2009. HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: Dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35, 428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329: 1071-1083.